PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31153915-3 2019 In this study, the effect of orexin receptor-2 (OX2R) and cannabinoid receptor-1 (CB1R) blockade were investigated in response to nicotine in male rats, on the neural activity of VTA. Nicotine 130-138 cannabinoid receptor 1 Rattus norvegicus 58-86 33150479-9 2021 CONCLUSIONS: In adult male rats, the reinforcement-enhancing effect of low-dose nicotine depends on nicotinic receptor stimulation and on neurotransmission via D1/D5 dopaminergic, opioid, alpha1-adrenergic, and CB1 cannabinoid receptors. Nicotine 80-88 cannabinoid receptor 1 Rattus norvegicus 211-214 24647948-0 2014 Nicotine self-administration induces CB1-dependent LTP in the bed nucleus of the stria terminalis. Nicotine 0-8 cannabinoid receptor 1 Rattus norvegicus 37-40 30017709-0 2018 Effects of concurrent blockade of OX2 and CB1 receptors in the ventral tegmental area on nicotine-induced place preference in rats. Nicotine 89-97 cannabinoid receptor 1 Rattus norvegicus 42-45 30017709-7 2018 The findings of this study support the possible role of OX2 and CB1 receptors in the VTA, in the acquisition and the expression of nicotine-induced place preference. Nicotine 131-139 cannabinoid receptor 1 Rattus norvegicus 64-67 29203303-0 2018 Interactive effects of morphine and nicotine on memory function depend on the central amygdala cannabinoid CB1 receptor function in rats. Nicotine 36-44 cannabinoid receptor 1 Rattus norvegicus 107-110 27737788-0 2017 Chronic FAAH inhibition during nicotine abstinence alters habenular CB1 receptor activity and precipitates depressive-like behaviors. Nicotine 31-39 cannabinoid receptor 1 Rattus norvegicus 68-71 27737788-9 2017 Taken together, our results suggest that chronic FAAH inhibition prevents the homeostatic adaptations of habenular CB1 receptor function that are necessary for the recovery from nicotine dependence. Nicotine 178-186 cannabinoid receptor 1 Rattus norvegicus 115-118 24468643-0 2014 Basolateral amygdala CB1 cannabinoid receptors mediate nicotine-induced place preference. Nicotine 55-63 cannabinoid receptor 1 Rattus norvegicus 21-24 24468643-1 2014 In the present study, the effects of bilateral microinjections of cannabinoid CB1 receptor agonist and antagonist into the basolateral amygdala (intra-BLA) on nicotine-induced place preference were examined in rats. Nicotine 159-167 cannabinoid receptor 1 Rattus norvegicus 78-81 24468643-5 2014 On the other hand, intra-BLA administration of AM251 (20-60 ng/rat), a selective cannabinoid CB1 receptor antagonist inhibited the acquisition of nicotine-induced place preference. Nicotine 146-154 cannabinoid receptor 1 Rattus norvegicus 93-96 30659912-0 2019 Functional crosstalk of nucleus accumbens CB1 and OX2 receptors in response to nicotine-induced place preference. Nicotine 79-87 cannabinoid receptor 1 Rattus norvegicus 42-45 29203303-5 2018 Furthermore, the blockade of the CeA cannabinoid CB1 receptors by the injection of AM251 (0.75 and 1ng/rat) reversed the potentiative effect of nicotine (0.6mg/kg, s.c.) on morphine-induced amnesia. Nicotine 144-152 cannabinoid receptor 1 Rattus norvegicus 49-52 29203303-7 2018 Confirmed by the cubic interpolation planes, the dose-response data revealed a cross-state-dependent learning between morphine and nicotine which may be mediated by the CeA endocannabinoid system via CB1 receptors. Nicotine 131-139 cannabinoid receptor 1 Rattus norvegicus 200-203 27493155-0 2016 The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability. Nicotine 105-113 cannabinoid receptor 1 Rattus norvegicus 4-7 27493155-3 2016 Here we evaluated the effects of the CB1 neutral antagonist AM4113 on the abuse-related effects of nicotine and its effects on anxiety and depressive-like behavior in rats. Nicotine 99-107 cannabinoid receptor 1 Rattus norvegicus 37-40 24647948-1 2014 Nicotine addiction is characterized by repetitive drug taking and drug seeking, both tightly controlled by cannabinoid CB1 receptors. Nicotine 0-8 cannabinoid receptor 1 Rattus norvegicus 119-122 22959963-0 2012 Nicotine-induced anxiety-like behavior in a rat model of the novelty-seeking phenotype is associated with long-lasting neuropeptidergic and neuroplastic adaptations in the amygdala: effects of the cannabinoid receptor 1 antagonist AM251. Nicotine 0-8 cannabinoid receptor 1 Rattus norvegicus 197-219 22784230-0 2013 Nicotine reinforcement is reduced by cannabinoid CB1 receptor blockade in the ventral tegmental area. Nicotine 0-8 cannabinoid receptor 1 Rattus norvegicus 49-52 22784230-1 2013 Cannabinoid type 1 (CB1) receptors control the motivational properties and reinforcing effects of nicotine. Nicotine 98-106 cannabinoid receptor 1 Rattus norvegicus 20-23 22784230-2 2013 Indeed, peripheral administration of a CB1 receptor antagonist dramatically decreases both nicotine taking and seeking. Nicotine 91-99 cannabinoid receptor 1 Rattus norvegicus 39-42 22784230-3 2013 However, the neural substrates through which the cannabinoid CB1 receptors regulate the voluntary intake of nicotine remain to be elucidated. Nicotine 108-116 cannabinoid receptor 1 Rattus norvegicus 61-64 22784230-4 2013 In the present study, we sought to determine whether central injections of a CB1 receptor antagonist delivered either into the ventral tegmental area (VTA) or the nucleus accumbens (NAC) may alter nicotine intravenous self-administration (IVSA). Nicotine 197-205 cannabinoid receptor 1 Rattus norvegicus 77-80 22784230-10 2013 These data suggest that in rats chronically exposed to nicotine IVSA, the cannabinoid CB1 receptors located in the VTA rather than in the NAC specifically control nicotine reinforcement and, subsequently, nicotine-taking behavior. Nicotine 55-63 cannabinoid receptor 1 Rattus norvegicus 86-89 22784230-10 2013 These data suggest that in rats chronically exposed to nicotine IVSA, the cannabinoid CB1 receptors located in the VTA rather than in the NAC specifically control nicotine reinforcement and, subsequently, nicotine-taking behavior. Nicotine 163-171 cannabinoid receptor 1 Rattus norvegicus 86-89 22784230-10 2013 These data suggest that in rats chronically exposed to nicotine IVSA, the cannabinoid CB1 receptors located in the VTA rather than in the NAC specifically control nicotine reinforcement and, subsequently, nicotine-taking behavior. Nicotine 163-171 cannabinoid receptor 1 Rattus norvegicus 86-89 23192660-9 2013 The content of the endocannabinoids N-arachidonylethanolamine and 2-arachidonoylglycerol, as well as the expression of cannabinoid receptor CB1 were up-regulated in brain tissues after nicotine delivery. Nicotine 185-193 cannabinoid receptor 1 Rattus norvegicus 140-143 22119710-2 2012 Present study investigates implication of cannabinoid receptor 1 (CB1R) in the basolateral (BLA) and the central (CeA) nuclei of amygdala in behaviorally sensitizing effects of nicotine and accompanying social anxiety following juvenile nicotine training and a 1- or 3-wk injection-free period in the novelty-seeking phenotype. Nicotine 177-185 cannabinoid receptor 1 Rattus norvegicus 42-70 22701425-3 2012 Results showed that the cannabinoid CB1 receptor antagonist SR141716A, but not the opioid receptor antagonist naloxone, reduced nicotine-induced premature responding, indicating that nicotine-induced motor impulsivity is cannabinoid, but not opioid receptor-dependent. Nicotine 128-136 cannabinoid receptor 1 Rattus norvegicus 36-39 22701425-3 2012 Results showed that the cannabinoid CB1 receptor antagonist SR141716A, but not the opioid receptor antagonist naloxone, reduced nicotine-induced premature responding, indicating that nicotine-induced motor impulsivity is cannabinoid, but not opioid receptor-dependent. Nicotine 183-191 cannabinoid receptor 1 Rattus norvegicus 36-39 22119710-2 2012 Present study investigates implication of cannabinoid receptor 1 (CB1R) in the basolateral (BLA) and the central (CeA) nuclei of amygdala in behaviorally sensitizing effects of nicotine and accompanying social anxiety following juvenile nicotine training and a 1- or 3-wk injection-free period in the novelty-seeking phenotype. Nicotine 237-245 cannabinoid receptor 1 Rattus norvegicus 42-70 21722663-0 2011 Cannabinoid CB1 receptor antagonist rimonabant disrupts nicotine reward-associated memory in rats. Nicotine 56-64 cannabinoid receptor 1 Rattus norvegicus 12-15 22291896-4 2012 CB1 receptors are expressed in the brain and modulate drug taking and drug seeking for various drugs of abuse, including nicotine. Nicotine 121-129 cannabinoid receptor 1 Rattus norvegicus 0-3 21521420-11 2012 These findings indicate that cannabinoid CB1-receptor stimulation increases the reinforcing effects of nicotine and precipitates relapse to nicotine-seeking behaviour in abstinent subjects. Nicotine 103-111 cannabinoid receptor 1 Rattus norvegicus 41-44 21521420-11 2012 These findings indicate that cannabinoid CB1-receptor stimulation increases the reinforcing effects of nicotine and precipitates relapse to nicotine-seeking behaviour in abstinent subjects. Nicotine 140-148 cannabinoid receptor 1 Rattus norvegicus 41-44 21521420-12 2012 Thus, modulating CB1-receptor signalling might have therapeutic value for treating nicotine dependence. Nicotine 83-91 cannabinoid receptor 1 Rattus norvegicus 17-20 21098863-5 2010 Finally, when we examined the influence of rimonabant (0.5, 1 and 2 mg/kg, ip), we found that this cannabinoid CB1 receptor antagonist attenuated reinstatement effect of ethanol priming as well as nicotine sensitization and locomotor cross-sensitization between nicotine and ethanol. Nicotine 197-205 cannabinoid receptor 1 Rattus norvegicus 111-114 20331563-10 2010 Additionally, the role of CB1 receptors in nicotine-motivated behaviours was extended to those controlled under a second-order schedule. Nicotine 43-51 cannabinoid receptor 1 Rattus norvegicus 26-29 20331564-0 2010 A second-order schedule of food reinforcement in rats to examine the role of CB1 receptors in the reinforcement-enhancing effects of nicotine. Nicotine 133-141 cannabinoid receptor 1 Rattus norvegicus 77-80 20331564-2 2010 Although endogenous cannabinoids acting on CB1 receptors have been implicated in the motivational effects of nicotine, their role in the "reinforcement-enhancing" properties of nicotine is unknown. Nicotine 109-117 cannabinoid receptor 1 Rattus norvegicus 43-46 20331564-10 2010 These data support and extend the hypothesis that nicotine can enhance the motivational value of reinforcing stimuli and suggest the increases in responding produced by nicotine involve CB1 receptors. Nicotine 169-177 cannabinoid receptor 1 Rattus norvegicus 186-189 21098863-6 2010 Our results indicate that similar endocannabinoid-dependent mechanisms re involved in the locomotor stimulant and reinforcing effects of nicotine and ethanol in rodents, and as such these data may provide further evidence for the use of cannabinoid CB1 receptor antagonists in treatment of tobacco addiction with or without concomitant ethanol dependence. Nicotine 137-145 cannabinoid receptor 1 Rattus norvegicus 249-252 21098863-5 2010 Finally, when we examined the influence of rimonabant (0.5, 1 and 2 mg/kg, ip), we found that this cannabinoid CB1 receptor antagonist attenuated reinstatement effect of ethanol priming as well as nicotine sensitization and locomotor cross-sensitization between nicotine and ethanol. Nicotine 262-270 cannabinoid receptor 1 Rattus norvegicus 111-114 19443943-2 2009 The aim of the present studies is to evaluate the role of CB1 cannabinoid receptors in the reinstatement of nicotine-induced conditioned place preference. Nicotine 108-116 cannabinoid receptor 1 Rattus norvegicus 58-61 20477753-6 2010 We found that URB597 blocked effects of nicotine and cocaine in the ShNAc through activation of both surface cannabinoid CB1-receptors and alpha-type peroxisome proliferator-activated nuclear receptor. Nicotine 40-48 cannabinoid receptor 1 Rattus norvegicus 121-124 18936914-3 2009 We tested the hypothesis that a cannabinoid receptor (CB) 1 antagonist that is in clinical trials for smoking cessation may reverse behaviorally sensitizing effects of nicotine in HRs and repeated nicotine-induced elevations in hippocampal 5HT. Nicotine 168-176 cannabinoid receptor 1 Rattus norvegicus 32-59 18936914-3 2009 We tested the hypothesis that a cannabinoid receptor (CB) 1 antagonist that is in clinical trials for smoking cessation may reverse behaviorally sensitizing effects of nicotine in HRs and repeated nicotine-induced elevations in hippocampal 5HT. Nicotine 197-205 cannabinoid receptor 1 Rattus norvegicus 32-59 18936914-11 2009 CONCLUSION: These data suggest that CB1 antagonists may prevent locomotor sensitization to nicotine and reverse nicotine-induced elevations in hippocampal 5HT in high novelty seekers. Nicotine 91-99 cannabinoid receptor 1 Rattus norvegicus 36-39 18936914-11 2009 CONCLUSION: These data suggest that CB1 antagonists may prevent locomotor sensitization to nicotine and reverse nicotine-induced elevations in hippocampal 5HT in high novelty seekers. Nicotine 112-120 cannabinoid receptor 1 Rattus norvegicus 36-39 19443943-4 2009 It was shown that the CB1 receptor antagonist AM 251 (0.25 and 0.5 mg/kg) in a dose-dependent manner attenuates the reinstatement of nicotine place conditioning. Nicotine 133-141 cannabinoid receptor 1 Rattus norvegicus 22-25 19443943-5 2009 These studies suggest a role for CB1 cannabinoids receptors in preventing the reinstatement of nicotine addiction. Nicotine 95-103 cannabinoid receptor 1 Rattus norvegicus 33-36 18588903-13 2008 Further, our results indicate that the endocannabinoid system is involved in context-induced relapse to nicotine seeking, and as such these data provide further evidence for the use of CB1 antagonists in smoking cessation. Nicotine 104-112 cannabinoid receptor 1 Rattus norvegicus 185-188 18054052-1 2008 The cannabinoid receptor subtype (CB1) antagonist rimonabant (SR141716) has been shown to decrease nicotine self-administration and attenuate nicotine-evoked dopamine release in the nucleus accumbens; effects that support recent findings on its clinical efficacy as a smoking cessation aid. Nicotine 99-107 cannabinoid receptor 1 Rattus norvegicus 34-37 18054052-1 2008 The cannabinoid receptor subtype (CB1) antagonist rimonabant (SR141716) has been shown to decrease nicotine self-administration and attenuate nicotine-evoked dopamine release in the nucleus accumbens; effects that support recent findings on its clinical efficacy as a smoking cessation aid. Nicotine 142-150 cannabinoid receptor 1 Rattus norvegicus 34-37 18054052-2 2008 The present experiments aim to advance our understanding on the role of CB1 receptors in rodent models of nicotine dependence. Nicotine 106-114 cannabinoid receptor 1 Rattus norvegicus 72-75 18054052-3 2008 AM251, a selective antagonist at CB1 receptors dose-dependently (1, 3 and 10mg/kg IP) suppressed intravenous nicotine (0.03mg/kg per infusion) self-administration in rats during three successive days of pre-treatment. Nicotine 109-117 cannabinoid receptor 1 Rattus norvegicus 33-36 18054052-8 2008 These preclinical findings support the use of rimonabant as a smoking cessation aid and highlight the CB1 receptor as a viable target to control intake of nicotine and prevent relapse. Nicotine 155-163 cannabinoid receptor 1 Rattus norvegicus 102-105 15986197-0 2005 Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats. Nicotine 66-74 cannabinoid receptor 1 Rattus norvegicus 12-15 17067804-0 2007 The CB1 cannabinoid receptor antagonist rimonabant chronically prevents the nicotine-induced relapse to alcohol. Nicotine 76-84 cannabinoid receptor 1 Rattus norvegicus 4-7 17067804-1 2007 Preclinical and clinical research shows that the cannabinoid brain receptor type 1 (CB(1)) modulates alcohol- and nicotine-related behaviors. Nicotine 114-122 cannabinoid receptor 1 Rattus norvegicus 61-89 15986197-13 2005 In contrast, the acute blockade of CB1 receptors no longer impairs the long-term control of behaviour by nicotine-associated environmental cues. Nicotine 105-113 cannabinoid receptor 1 Rattus norvegicus 35-38 16969683-1 2006 RATIONALE: We previously reported that the CB1 cannabinoid receptor antagonist, rimonabant, impaired the acquisition and the short-term (24 h), but not long-term (3 weeks), expression of conditioned place preference (CPP) induced by nicotine in rats. Nicotine 233-241 cannabinoid receptor 1 Rattus norvegicus 43-46 16969683-11 2006 However, endocannabinoid-dependent mechanisms are critically involved in the development of the neuroadaptive changes responsible for the shift from CB1-dependent to CB1-independent expression of nicotine incentive learning. Nicotine 196-204 cannabinoid receptor 1 Rattus norvegicus 149-152 16969683-11 2006 However, endocannabinoid-dependent mechanisms are critically involved in the development of the neuroadaptive changes responsible for the shift from CB1-dependent to CB1-independent expression of nicotine incentive learning. Nicotine 196-204 cannabinoid receptor 1 Rattus norvegicus 166-169 15986197-2 2005 OBJECTIVES: The objective of the study is to evaluate whether activation of CB1 cannabinoid receptors is necessary for the establishment and the short- and long-term expression of nicotine-induced conditioned place preference (CPP). Nicotine 180-188 cannabinoid receptor 1 Rattus norvegicus 76-79 15486497-0 2004 Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. Nicotine 37-45 cannabinoid receptor 1 Rattus norvegicus 14-17 15935455-0 2005 CB1 receptor antagonists for the treatment of nicotine addiction. Nicotine 46-54 cannabinoid receptor 1 Rattus norvegicus 0-3 15935455-9 2005 The selective CB1 antagonist, rimonabant (SR141716), reduces nicotine self-administration and nicotine-seeking behavior induced by conditioned cues in rats. Nicotine 61-69 cannabinoid receptor 1 Rattus norvegicus 14-17 15935455-9 2005 The selective CB1 antagonist, rimonabant (SR141716), reduces nicotine self-administration and nicotine-seeking behavior induced by conditioned cues in rats. Nicotine 94-102 cannabinoid receptor 1 Rattus norvegicus 14-17 15292905-0 2005 Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Nicotine 0-8 cannabinoid receptor 1 Rattus norvegicus 138-141